GeoVax Labs (NASDAQ:GOVX) Posts Earnings Results, Beats Estimates By $15.60 EPS

GeoVax Labs (NASDAQ:GOVX) issued its quarterly earnings results on Thursday. The company reported ($10.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.16) by $15.60, FiscalAI reports.

GeoVax Labs Stock Performance

Shares of GeoVax Labs stock traded down $0.12 on Thursday, hitting $2.04. 125,927 shares of the company traded hands, compared to its average volume of 42,020. The business has a 50-day simple moving average of $6.91 and a 200 day simple moving average of $27.58. GeoVax Labs has a 52 week low of $1.84 and a 52 week high of $300.00. The stock has a market capitalization of $632,400.00, a P/E ratio of -0.18 and a beta of 3.85.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GOVX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, October 15th. Noble Financial restated an “outperform” rating on shares of GeoVax Labs in a report on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3,600.00.

About GeoVax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.